Loading this company
ICON Public Limited Company
ICLRPrices in USD
TickerWorth ScoreD41/100
What we think
Too wide to call. Our lenses land between $71.11 and $206.33, which is too broad to say where today’s price sits in it.
Price
$168.79USD down −$1.39 (−0.82%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:53 UTC (7 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$71.11–$206.33
What the price needs: revenue growth of 21.4%/yr for 5 years (our model assumes 6.8%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $168.79Priced · Prices are delayed.
Is it a good business?
- Valuation33 out of 100
- Growth50 out of 100
- Financial health33 out of 100
- Past performance33 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$187.76 across 17 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It operates in the Diagnostics & Research industry (Healthcare sector), headquartered in Ireland. The company employs roughly 40,200 people.
Revenue: Ireland 39% · United States 31% · Rest of Europe 19% · Rest of World 12%
Key stats
52-week range$66.57–$203.91
- Open
- $169.25
- Day high
- $173.11
- Day low
- $167.90
- Previous close
- $170.18
- Volume
- 176,585 · 0.21× avg
- Average volume
- 847,734
- Market cap
- $13,022,858,240.00
- P/E (TTM)
- 177.67
- Earnings per share
- $0.95
- Beta
- 1.24
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
No filings or corporate activity on file in the recent window.
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- McCague Eugene PacelliOption exercise · $409,283.70
- McCague Eugene PacelliOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.